RxDoctor Payments DataLook up a doctor →

Kristen Allard

Family · Eldersburg, MDNPI 1245892819

Payments from drug & device makers

$8,928in general payments, 2019–2025

Across 500 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$863
  • Novo Nordisk$792
  • Amgen$791
  • Pfizer$772
  • Bausch Health US, LLC$395
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$8,84399%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,928 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$85,833
Medicare patients
249
Services billed
1,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$50,652
JardianceEmpagliflozin19$27,138
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$22,173
EliquisApixaban14$13,242
Rosuvastatin Calcium119$3,655
SynthroidLevothyroxine Sodium14$1,792
Atorvastatin Calcium126$1,775
Albuterol Sulfate HfaAlbuterol Sulfate40$974
Escitalopram Oxalate57$959
Ezetimibe20$904
Duloxetine Hcl19$853
Levothyroxine Sodium92$796
Amlodipine Besylate88$731
Lisinopril89$699
Bupropion XlBupropion Hcl16$670

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$792$50,65237 claims
Boehringer IngelheimJardiance$213$27,13819 claims
GSKTrelegy Ellipta$92$22,17316 claims
PfizerEliquis$772$13,24214 claims
AbbVieSynthroid$1,556$1,79214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,843 family providers in Maryland.

Other family in Eldersburg

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →